Catalyst overview
Research summary
This catalyst tracks a PDUFA approval decision for PYRUKYND (Mitapivat) in Sickle cell disease, Anemia. The expected timing is based on the latest available company guidance and may change.
07/30/26:- REIGNITE Ph3 dosed first patient; Saudi SCD filing completed. PDUFA remains November 1, 2026.
Verification
Confirm timing and program details against the company announcement or filing.